Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The portfolio had a 5.7% gain in the first quarter compared to an 8.2% return in the Russell Midcap Value Index. The Strategy underperformed in Financials and Industrials due to a low hit rate on stock selection. In addition, you can check the top 5 holdings of the fund to know its best picks in 2024. Heartland Mid Cap Value Fund featured stocks like Perrigo Company plc (NYSE:PRGO) in the Q1 2024 investor letter. Headquartered in Dublin, Ireland, Perrigo Company plc (NYSE:PRGO) provides over-the-counter health and wellness solutions. On April 12, 2024, Perrigo Company plc (NYSE:PRGO) stock closed at $30.32 per share. One-month return of Perrigo Company plc (NYSE:PRGO) was 1.03%, and its shares lost 17.65% of their value over the last 52 weeks. Perrigo Company plc (NYSE:PRGO) has a market capitalization of $4.109 billion. Heartland Mid Cap Value Fund stated the following regarding Perrigo Company plc (NYSE:PRGO) in its first quarter 2024 investor letter: "Healthcare. Perrigo Company plc (NYSE:PRGO) is an existing deep value holding that has slumped lately, but we’re encouraged by the self-help progress. Shares of the consumer health company, with private-label brands spanning allergy and pain relief to digestive health products, fell in response to news that the cost to remediate its infant formula plants will run higher than expected. Last September, the Food and Drug Administration updated industry guidelines for the agency’s approach to inspections and compliance for infant formula production. This included more frequent cleaning of manufacturing facilities, resulting in a slowdown in production…” (Click here to read the full text) 5 Highest Paying Countries for Doctors A doctor and a patient discussing the benefits of OTC health and wellness solutions. Perrigo Company plc (NYSE:PRGO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. At the end of the fourth quarter, Perrigo Company plc (NYSE:PRGO) was held by 41 hedge fund portfolios, compared to 31 in the previous quarter, according to our database. We previously discussed Perrigo Company plc (NYSE:PRGO) in another article, where we shared the list of most undervalued pharmaceutical stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q1 2024 page for more investor letters from hedge funds and other leading investors. Suggested Articles: 10 Buy-Rated Stocks with Latest Insider Purchases 20 Metros with the Highest Gains in Active Home Inventory in the US 10 Unstoppable Stocks That Will Make You Richer Disclosure: None. This article is originally published at Insider Monkey.
Here’s Why Perrigo Company PLC (PRGO) Stock Slumped in Q1
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...